Last reviewed · How we verify
Octreotide LAR
Octreotide LAR is a long-acting somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone, insulin, and other hormones.
Octreotide LAR is a long-acting somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone, insulin, and other hormones. Used for Acromegaly, Carcinoid syndrome, Variceal bleeding in portal hypertension.
At a glance
| Generic name | Octreotide LAR |
|---|---|
| Also known as | Sandostatin, Sandostatin LAR®, Sandostatin® LAR, SOM230, SANDOSTATIN LAR, Octreotide |
| Sponsor | Cedars-Sinai Medical Center |
| Drug class | Somatostatin analog |
| Target | Somatostatin receptors (SSTR2, SSTR5) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology, Oncology |
| Phase | FDA-approved |
Mechanism of action
Octreotide mimics somatostatin, a natural inhibitory hormone, by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells. This suppresses the release of growth hormone, insulin-like growth factor-1 (IGF-1), and other peptide hormones. The LAR (long-acting release) formulation provides sustained therapeutic levels over 4 weeks via intramuscular injection.
Approved indications
- Acromegaly
- Neuroendocrine tumors (carcinoid syndrome, VIPomas)
- Gastroenteropancreatic neuroendocrine tumors
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
- Headache
- Injection site pain
- Cholelithiasis (gallstones)
- Hyperglycemia
Key clinical trials
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (PHASE3)
- Hoffa's Fat Pad Impingement (HFPI) (PHASE4)
- Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET (PHASE3)
- Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (PHASE1)
- Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (PHASE3)
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (PHASE1)
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (PHASE3)
- 177Lu-DOTATATE for Recurrent Meningioma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Octreotide LAR CI brief — competitive landscape report
- Octreotide LAR updates RSS · CI watch RSS
- Cedars-Sinai Medical Center portfolio CI